Cogent Biosciences Income Statement (2017-2026) | COGT

Income Statement Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
39.83M39.85M43.81M45.82M49.39M69.86M69.89M70.95M85.33M86.12M86.12M95.61M109.34M110.46M110.46M113.86M113.93M139.83M128.90M170.77M
Revenue & cost
Revenue (Quarter)
Operating items
Research & Development (Quarter)
12.39M14.80M20.51M25.47M29.48M29.94M36.74M36.04M38.87M50.13M48.72M52.70M54.29M63.61M62.05M63.03M62.20M68.99M75.56M75.36M
Selling, General & Administrative (Quarter)
4.90M5.02M5.13M5.95M6.38M6.88M7.00M7.20M8.21M9.45M9.51M9.70M10.09M11.80M11.69M11.90M13.38M14.37M23.93M28.24M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
17.29M19.82M25.64M31.42M35.85M36.82M43.74M43.24M47.09M59.58M58.23M62.40M64.39M75.41M73.73M74.93M75.58M83.36M99.49M103.61M
Operating Income (Quarter)
-17.29M-19.82M-25.64M-31.42M-35.85M-36.82M-43.74M-43.24M-47.09M-59.58M-58.23M-62.40M-64.39M-75.41M-73.73M-74.93M-75.58M-83.36M-99.49M-103.61M
EBIT (Quarter)
-17.29M-19.82M-25.64M-31.42M-35.85M-36.82M-43.74M-43.24M-47.09M-59.58M-58.23M-62.40M-64.39M-75.41M-73.73M-74.93M-75.58M-83.36M-99.49M-103.61M
Non-operating items
Interest & Investment Income (Quarter)
0.12M0.12M-0.36M0.11M0.27M1.50M4.15M0.12M-0.11M-0.07M0.42M-0.28M-0.15M1.09M17.44M2.95M-0.15M3.89M-9.30M-0.77M
Other Non Operating Income (Quarter)
0.62M0.62M0.62M0.68M0.66M0.26M0.66M0.68M0.27M-0.01M-0.00M0.04M0.00M1.95M-0.01M-0.01M-0.00M-0.01M-0.14M
Non Operating Income (Quarter)
0.74M0.73M0.73M0.78M0.93M1.76M4.13M4.65M3.01M4.20M3.86M4.06M5.44M4.78M5.81M2.95M2.05M2.42M-3.00M6.25M
Net income details
EBT (Quarter)
-21.73M-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-56.30M-71.98M-75.98M-85.22M-110.10M-111.20M
Profit After Tax (Quarter)
-16.55M-19.08M-24.91M-30.63M-34.93M-35.23M-39.45M-8.53M-45.31M-58.35M-58.95M-70.63M-3.44M-72.27M-73.53M-80.93M-102.50M-97.35M
Income from Continuing Operations (Quarter)
-21.73M-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-56.30M-71.98M-75.98M-85.22M-110.10M-111.20M
Consolidated Net Income (Quarter)
-21.73M-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-56.30M-71.98M-75.98M-85.22M-110.10M-111.20M
Income towards Parent Company (Quarter)
-21.73M-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-56.30M-71.98M-75.98M-85.22M-110.10M-111.20M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-21.73M-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-56.30M-71.98M-75.98M-85.22M-110.10M-111.20M
Additional items
EPS (Basic) (Quarter)
-0.57-0.51-0.69-0.80-1.51-0.69-0.68-0.61-0.63-0.69-0.74-0.66-0.65-0.67-0.54-0.64-0.66-0.62-0.85-0.69
EPS (Diluted) (Quarter)
-0.57-0.51-0.69-0.80-1.51-0.69-0.68-0.61-0.63-0.69-0.74-0.66-0.65-0.67-0.54-0.64-0.66-0.62-0.85-0.69
Shares Outstanding (Quarter)
38.44M39.85M38.73M45.11M49.39M69.58M58.74M70.73M74.75M86.17M79.66M94.80M99.24M110.17M103.86M113.31M114.47M137.55M128.90M162.19M
Shares Outstanding (Diluted) (Quarter)
38.44M39.85M38.73M45.11M49.39M69.58M58.74M70.73M74.75M86.17M79.66M94.80M99.24M110.17M103.86M113.31M114.47M137.55M128.90M162.19M
EBITDA (Quarter)
-17.29M-19.82M-25.64M-31.42M-35.85M-36.82M-43.74M-43.24M-47.09M-59.58M-58.23M-62.40M-64.39M-75.41M-73.73M-74.93M-75.58M-83.36M-99.49M-103.61M
Interest Expenses (Quarter)
4.56M0.46M0.82M4.60M39.04M12.71M0.39M0.10M0.17M1.18M0.06M0.19M0.00M0.25M5.75M1.30M6.83M